US Bancorp’s Bright Minds Biosciences DRUG Stock Holding History

US Bancorp’s Portfolio DRUG Stock Details DRUG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-26	Closed	-$937	–	4245
2024 Q4	$937	Buy	+26	New	+$915	﹤0.01%	3962

Other funds holding DRUG

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

US Bancorp's DRUG Position: Q1 2025 in Review

US Bancorp sold out of Bright Minds Biosciences (DRUG) in Q1 2025, closing a stake of 26 shares — an estimated $937 sold.

US Bancorp first reported a position in DRUG in Q4 2024 and held it in 1 quarter. The position peaked at $937 in Q4 2024. 34 funds tracked by Wall St. Rank hold DRUG as of Q1 2025.

US Bancorp reported no remaining Bright Minds Biosciences position as of Q1 2025 after selling out during the quarter.
US Bancorp sold 26 Bright Minds Biosciences shares in Q1 2025, an estimated $937.
US Bancorp first reported a position in Bright Minds Biosciences in Q4 2024 and held it in 1 quarter.
US Bancorp's Bright Minds Biosciences position peaked at $937 in Q4 2024.
34 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2025.

Based on US Bancorp's 13F filing for Q1 2025, filed 8 May 2025.